AREC.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 10:34):

Stats
Today's Volume	29 146.00
Average Volume	14 170.00
Market Cap	41.62M
EPS	£0 ( 2024-04-21 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-4.38
ATR14	£1.503 (1.11%)

Arecor Therapeutics plc Correlation

10 Most Positive Correlations

10 Most Negative Correlations
DPEU.L	-0.848
LRE.L	-0.811
RMMC.L	-0.807

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arecor Therapeutics plc Financials

Annual	2022
Revenue:	£2.40M
Gross Profit:	£2.40M (100.00 %)
EPS:	£-0.320

Q2	2023
Revenue:	£1.67M
Gross Profit:	£1.37M (81.97 %)
EPS:	£-0.150

Q1	2023
Revenue:	£834 500
Gross Profit:	£834 500 (100.00 %)
EPS:	£-0.0739

Q4	2022
Revenue:	£1.71M
Gross Profit:	£855 000 (50.00 %)
EPS:	£-0.160

Financial Reports:

No articles found.

Arecor Therapeutics plc

Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.